Only English submissions are accepted. The accepted authors will participate in the poster display at the conference and share their research results with colleagues. Excellent authors have the opportunity to speak at the conference and enjoy free registration fees to attend. Welcome to contribute!
(1) Submission content
ECLS basic and translational science (ECLS experimental research, basic research), ECLS clinical research (randomized controlled trials, cohort studies, case reports), new advances in ECLS technology, prevention of ECLS related complications and control of risk factors, etc. Reviews are not accepted.
(2) Submission form
1. Abstract: Written in the order of purpose, method, result and conclusion, no more than 500 words, can be attached to a figure/table;
2. Case report: clear logic, no more than 800 words, can be attached to a chart/table;
3. Full text: Refer to the form of magazine submission, about 4000 words. Excellent papers will have the opportunity to be recommended for publication in the current issue of SCI journal. Please indicate the author's contact information (telephone /e-mail/ work address) when submitting the paper. It must be an unpublished paper.
(3) Submission requirements
1. The content of all essays shall be true, scientific, advanced and practical, and shall not involve confidentiality, and the signature shall be non-controversial.
2. Submission must be real name, please check carefully before clicking submit to make sure that the author and unit are correct. Please keep your own copy. Please confirm the accuracy of your personal information before submission to ensure that the notification of recruitment, participation and communication can be delivered in time.
3. For any revision or withdrawal, please apply by phone or email within one week after receiving the original notice. Please check the email or check the selection results online after the review results. Once the selection is made, the application for revision and withdrawal will no longer be accepted.
Submission Deadline: April 30, 2025